Correction: Analytical validation of NeXT Personal &#x00AE; , an ultra-sensitive personalized circulating tumor DNA assay

Josette Northcott; Gabor Bartha; Jason Harris; Conan Li; Fabio C.P. Navarro; Rachel Marty Pyke; Manqing Hong; Qi Zhang; Shuyuan Ma; Tina X. Chen; Janet Lai; Nitin Udar; Juan-Sebastian Saldivar; Erin Ayash; Joshua Anderson; Jiang Li; Tiange Cui; Tu Le; Ruthie Chow; Randy Jerel Velasco; Chris Mallo; Rose Santiago; Robert C. Bruce; Laurie J. Goodman; Yi Chen; Dan Norton; Richard O. Chen; John M. Lyle

doi:10.18632/oncotarget.28581

Oncotarget

On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed.
Learn more.

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Analytical validation of NeXT Personal^®, an ultra-sensitive personalized circulating tumor DNA assay

PDF | How to cite

Oncotarget. 2024; 15:407-407. https://doi.org/10.18632/oncotarget.28581

Metrics: PDF 142 views | ?

Josette Northcott¹, Gabor Bartha¹, Jason Harris¹, Conan Li¹, Fabio C.P. Navarro¹, Rachel Marty Pyke¹, Manqing Hong¹, Qi Zhang¹, Shuyuan Ma¹, Tina X. Chen¹, Janet Lai¹, Nitin Udar¹, Juan-Sebastian Saldivar¹, Erin Ayash¹, Joshua Anderson¹, Jiang Li¹, Tiange Cu¹, Tu Le¹, Ruthie Chow¹, Randy Jerel Velasco¹, Chris Mallo¹, Rose Santiago¹, Robert C. Bruce¹, Laurie J. Goodman¹, Yi Chen¹, Dan Norton¹, Richard O. Chen^1,* and John M. Lyle^1,*

¹Personalis, Inc., Fremont, CA 94555, USA
^*Co-last authors

Published: June 20, 2024

Copyright: © 2024 Northcott et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: The following author has been added to the author list:

Massimo Morra
¹Personalis, Inc., Fremont, CA 94555, USA

Original article: Oncotarget. 2024; 15:200–2018. DOI: https://doi.org/10.18632/oncotarget.28565

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28581

Announcements

Publication Alerts

Corrections:

Correction: Analytical validation of NeXT Personal^®, an ultra-sensitive personalized circulating tumor DNA assay

Announcements

Publication Alerts

Corrections:

Correction: Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay

Correction: Analytical validation of NeXT Personal^®, an ultra-sensitive personalized circulating tumor DNA assay